In today’s podcast, Crinetics co-founders Dr. Scott Struthers and Dr. Steve Betz share their views and experiences in drug discovery and development, revealing what it really takes to bring a new medication from concept to patients.
Acromegaly
Acromegaly is usually caused by a noncancerous tumor. Middle-aged adults are most commonly affected. Symptoms include enlargement of the face, hands, and feet. Prompt treatment is needed to avoid serious illness. Drugs can reduce the effects of growth hormone. If needed, surgery and radiation may be used to remove tumor cells.
Inside Camurus: Dr. Markus Johnsson talks about FluidCrystal® technology and next-generation treatment innovations
January 19, 2026
In the latest episode of the Pituitary World News podcast, Jorge D. Faccinetti sits down with Dr. Markus Johnsson, Senior VP of R&D at Camurus, to explore the fascinating world of FluidCrystal® technology. This innovative approach promises to revolutionize the way we think about drug delivery, providing long-lasting solutions for chronic diseases particularly for people with acromegaly.
New 3-Month Octreotide Formulation Enters Phase 3 Testing for Acromegaly
December 4, 2025
In an important new development Swiss-based Debiopharm entered a Phase 3 trial of a new Octreotide formulation. The company is currently recruiting patients for the study. Debio 4126 is a sustained-release formulation designed to improve the convenience of somatostatin analogue (SSA) therapy for the treatment of acromegaly.
Game Changers: An AI Facial Recognition System that detects acromegaly 10 years before diagnosis
October 30, 2025
Could artificial intelligence and machine learning recognize the early, subtle changes in people’s faces associated with the hormonal disease acromegaly? New research spearheaded by Dr. Manel Puig-Domingo and outlined in a recent paper published in the journal PITUITARY raises the possibility that AI algorithms and machine learning could provide a game-changing approach to the early diagnosis of this complex disease, which now takes an average of 6 to 10 years to diagnose.
Big News for Acromegaly: Crinetics Announces FDA Approval of PALSONIFY™
September 26, 2025
Crinetics announced today that the FDA has approved PALSONIFY™, the first once-daily oral therapy to treat acromegaly. The company announced the drug will be available in early October.
Camurus: an inside look and my conversation with CEO Fredrik Tiberg
July 7, 2025
I recently had the pleasure of meeting Camurus CEO Fredrik Tiberg. We initially connected on a Zoom call and later met at the European Endocrine Conference held in Copenhagen, Denmark in May. We agreed to meet in person, learn more about the company and record a podcast.
With a new acromegaly drug in the horizon Crinetics launches new patient support websites
June 10, 2025
From the desk of J D Faccinetti – co Founder and chief editor – Today, I am pleased to share two new excellent resources from Crinetics Phamaceuticals: AcromegalyReality.com – This newly launched site offers support
Pituitary Grand Rounds Episode 8: Acromegaly Insights — A Case Discussion with Two Physicians and Their Fellows
April 14, 2025
This captivating conversation offers an intimate look at how endocrine fellows train on pituitary disorders and their confidence in managing these conditions post-fellowship.
Acromegaly: a discussion about psychological and emotional health support initiatives
February 27, 2025
Today's podcast is about an important Chiesi Rare Diseases initiative to learn more about the psychological, social, and emotional health issues facing acromegaly patients. We talked to Stuart Siedman, Chiesi's Vice President of advocacy. Stuart
Two leading acromegaly experts discuss promising treatment options
January 7, 2025
In today's podcast, we are excited to welcome Dr. Joanna Spencer-Segal, a research assistant professor at the Michigan Neuroscience Institute and an assistant professor in the Department of Internal Medicine, Division of Metabolism, Endocrinology, and
Pituitary Grand Rounds, Episode 6: Controversies in the Management of Acromegaly
December 2, 2024
This fantastic presentation by Dr. John Carmichael, Distinguished Professor of Clinical Medicine at the University of Southern California and Co-director of the USC Pituitary Center focuses on the controversies arising from the clinical dilemmas present in treating a complicated condition like acromegaly.
Machine learning technology promises early diagnosis for acromegaly
October 31, 2024
SAN FRANCISCO, BARCELONA, TORONTO – October 31, 2024 – Artificial Intelligence (AI) could play a significant role in aiding the diagnosis of rare diseases. This is especially true for facial recognition and machine learning in
Musings on Tea and Acromegaly in Connemara
October 24, 2024
From J D Faccinetti, co-founder – It is often said that once you know people with acromegaly, you will see it more often. It makes you wonder how apt the definition of “rare” is for